Mesoblast (MESO) Non-Current Debt (2018)
Mesoblast (MESO) posted Non-Current Debt of -$149.3 million for Q4 2025, down 192.43% sequentially from $161.6 million in Q2 2025, and down 7.0% YoY from -$160.6 million in Q4 2024.
Analysis
Mesoblast (MESO) Non-Current Debt (2018) Analysis & Trends
Mesoblast has reported Non-Current Debt for 8 years, with the latest figure at -$149.3 million in Q4 2025.
- Quarterly Non-Current Debt fell 7.0% year-over-year to -$149.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$149.3 million (down 7.0% YoY) and the FY2025 annual result came in at $161.6 million, up 60.77% from the prior year.
- Non-Current Debt declined to -$149.3 million in Q4 2025 per MESO's latest filing, from $161.6 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $161.6 million in Q2 2025 and troughed at -$149.3 million in Q4 2025.
- A 5-year average of $13.5 million and a median of $42.7 million in 2021 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2022 and 2023: Non-Current Debt jumped 123.21% in 2022, then slumped 234.31% in 2023.
- Over 5 years, Non-Current Debt stood at $86.5 million in 2021, then plunged by 233.71% to -$115.7 million in 2022, then decreased by 6.29% to -$123.0 million in 2023, then declined by 13.46% to -$139.5 million in 2024, then retreated by 7.0% to -$149.3 million in 2025.
- According to Business Quant data, Non-Current Debt over the past three periods registered -$149.3 million, $161.6 million, and -$139.5 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 591.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 882.16 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 8.96 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2018 | 61.16 Mn |
| Jun 30, 2018 | 59.40 Mn |
| Mar 31, 2018 | 31.42 Mn |